[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100340977":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":40,"centralContacts":45,"locations":52,"responsibleParty":71,"collaborators":50,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":50,"enrollmentInfo":83,"targetDuration":50,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":54,"whyStopped":50,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Robot-assisted radical hysterectomy","EXPERIMENTAL","Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy",[13,14],"Procedure: Robot-assisted radical hysterectomy","Diagnostic Test: Sentinel lymph node biopsy",{"label":16,"type":17,"description":11,"interventionNames":18},"Abdominal radical hysterectomy","ACTIVE_COMPARATOR",[19,14],"Procedure: Abdominal radical hysterectomy",[21,28,33],{"type":22,"name":16,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Radical hysterectomy (type B or C according to the Querleu\\&Morrow classification) with pelvic lymphadenectomy",[16],[26,27],"TARH","Open radical hysterectomy",{"type":22,"name":9,"description":23,"armGroupLabels":29,"otherNames":30},[9],[31,32],"TRRH","Robotic radical hysterectomy",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DIAGNOSTIC_TEST","Sentinel lymph node biopsy","Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)",[16,9],[39],"SLN",[41],{"name":42,"affiliation":43,"role":44},"Henrik Falconer, PhD","Karolinska University Hospital","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Katja Wiklund","CONTACT","+46 8 123 725 84",null,"katja.wiklund@regionstockholm.se",[53],{"facility":43,"status":54,"city":55,"state":50,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Stockholm","17176","Sweden","SE",{"type":60,"coordinates":61},"Point",[62,63],18.06871,59.32938,{"lat":63,"lon":62},[66,70],{"name":67,"role":48,"phone":68,"phoneExt":50,"email":69},"Henrik Falconer, MD, PhD","+46707742146","henrik.falconer@karolinska.se",{"name":67,"role":44,"phone":50,"phoneExt":50,"email":50},{"type":44,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":50,"oldOrganization":50},"Henrik Falconer","Head of GYN Oncology","100340977","robot-assisted-approach-to-cervical-cancer-100340977",false,"NCT03719547","Robot-assisted Approach to Cervical Cancer","RACC","Inclusion Criteria:\n\n* Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adeno-squamous carcinoma of the uterine cervix;\n* Patients with histologically confirmed stage IB (IB3 excluded) and IIA1, according to the latest revision of the FIGO staging manual\n* Patients undergoing either a Type B or C radical hysterectomy (Querleu and Morrow classification)\n* Patients with adequate bone marrow, renal and hepatic function\n* ECOG Performance Status of 0, 1 or 2.\n* Patient must be suitable candidates for surgery.\n* Patients who have signed an approved Informed Consent\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Any histology other than adenocarcinoma, squamous cell carcinoma or adeno-squamous carcinoma of the uterine cervix\n* Tumor size greater than 4 cm\n* FIGO stage II-IV (except IIA1)\n* Patients with a history of pelvic or abdominal radiotherapy\n* Patients who are pregnant\n* Patients with contraindications to surgery\n* Patients with evidence of metastatic disease by conventional imaging, enlarged pelvic or aortic lymph nodes \\> 2cm; or histologically positive lymph nodes\n* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)\n* Patients unable to withstand prolonged lithotomy and steep Trendelenburg position\n* Patients with secondary invasive neoplasm in the last 5 years (except non-melanoma skin cancer, breast cancer T1N0M0 grade 1 or 2 without any signs of recurrence or activity)","FEMALE","18 Years",{"count":84,"type":85},800,"ESTIMATED","INTERVENTIONAL",[88],"NA","The purpose of the RACC trial is to compare the oncologic outcome defined as recurrence-free survival (RFS) between robot-assisted and open radical hysterectomy for the treatment of early stage cervical cancer.",[91],"Cervical Cancer",[93,94,95,96,97,98],"Cervical cancer","Robot-assisted surgery","Sentinel node biopsy","Laparotomy","Recurrence","Survival","2026-08-04",{"date":101,"type":102},"2026-08-07","ACTUAL",{"date":104,"type":102},"2019-05-28",{"date":106,"type":85},"2027-12-31",{"name":5,"class":6},1]